UK Biobank opens its data box
Enlarge image

BusinessUK

UK Biobank opens its data box

02.04.2012 - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia.

The resource, which contains some 1,000 pieces of health and lifestyle information approx 500,000 participants aged 40-69 when they joined the four-year project, will continue to be updated with additional information and the results of research carried out on its data. It currently contains about 20 TB (terabytes) of securely stored data.
Amongst the half a million Britons delivering data, are 26,000 people with diabetes and 50,000 with joint disorders, 41,000 teetotallers, and 11,000 heart attack patients. Scientists will be granted access to the data if they can show that their research is health-related and in the public interest. They do not have to be from or based in the UK, and it will not matter if they are from academia, industry, charities or governments. Successful applications will be published on the website. UK Biobank is funded by the Wellcome Trust, Medical Research Council, Department of Health, Scottish Government, Welsh Government and the British Heart Foundation. Professor Sir Mike Rawlins, chair of the UK's National Institute of Health and Clinical Excellence (NICE), has been announced as chairman of the organisation, replacing Sir Alan Langlands, chief executive of the Higher Education Funding Council for England, and former CEO of the NHS, who over the past eight years has steered the project through its establishment and early phases.

http://www.european-biotechnology-news.com/news/news/2012-02/uk-biobank-opens-its-data-box.html

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto discussing a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%

FLOP

  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%

TOP

  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%

FLOP

  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%

TOP

  • SANTHERA96.45 CHF2323.4%
  • WILEX4.33 EUR397.7%
  • CYTOS1.01 CHF359.1%

FLOP

  • MOLOGEN4.94 EUR-55.2%
  • BIOFRONTERA2.30 EUR-27.7%
  • EPIGENOMICS5.60 EUR-20.0%

No liability assumed, Date: 04.05.2015